Treatment of Ulcerative Skin Lesions in Crohn's Disease

Introduction to Treatment Approach

The American Gastroenterological Association recommends anti-TNF-α biologics, particularly infliximab, as first-line therapy for patients with Crohn's disease presenting with ulcerative skin lesions, due to their proven efficacy in treating both intestinal and cutaneous manifestations of the disease 1

The European Crohn’s and Colitis Organisation suggests ruling out infection as a potential cause or complication of skin lesions 2

The American Gastroenterological Association recommends anti-TNF-α agents, particularly infliximab, for treating fistulizing and cutaneous manifestations of Crohn's disease, with an recommended induction dosing of IV infliximab with weight-based dosing, and maintenance dosing to prevent recurrence 1, 3
The American Gastroenterological Association suggests vedolizumab as an alternative option for patients with primary non-response to TNF-α inhibitors 1

The European Crohn’s and Colitis Organisation recommends antibiotics, particularly metronidazole, for specific types of cutaneous lesions, especially those with infectious components 2
The American Gastroenterological Association suggests immunomodulators, such as azathioprine, in combination with biologics for enhanced efficacy 1

The American Gastroenterological Association recommends surgical drainage for perianal lesions, such as abscesses and fistulas, if fluctuant 4, 5
The American Gastroenterological Association advises against surgical excision of skin tags associated with Crohn's disease due to high risk of complications and poor wound healing 4, 5
The American Gastroenterological Association suggests that anal fissures in Crohn's disease are often painless and heal spontaneously in >80% of cases, and surgical intervention should be limited 4

The European Crohn’s and Colitis Organisation recommends regular assessment of both cutaneous and intestinal disease activity 2
The American Gastroenterological Association suggests adjusting therapy based on clinical response of both skin and intestinal manifestations 1

The American Gastroenterological Association advises against delaying biologic therapy in patients with moderate-to-severe disease, and recommends early introduction of biologics with or without immunomodulators 1
The European Crohn’s and Colitis Organisation recommends avoiding reliance solely on corticosteroids for maintenance therapy, as they are not effective for long-term disease control 2
The American Academy of Dermatology suggests being cautious with IL-17 inhibitors, such as secukinumab, which may paradoxically worsen intestinal Crohn's disease 6